

**REMARKS:**

In the Office Action dated July 26, 2006, claims 32-56 and 63, in the above-identified U.S. patent application were subject to restriction. Claims 1-31 have been canceled, claims 57-62 and 64 have been withdrawn and claims 32-56 and 63 remain in the application. Claim 32 has been amended to recite "antisense oligonucleotide" instead of "antibody". The term "antibody" was erroneously recited in the previously submitted claims but the present invention is not directed to antibodies as is clear from the present specification.

The office action indicates that the computer readable form of the sequence listing was not placed in the file at the Patent Office. A second copy of the CRF is attached to this response along with the required statement and copy of the Notice to Comply.

Applicants hereby elect group I, claims 32-56 and 63 and the ASO corresponding to SEQ ID NO:30 for prosecution in the present application with traverse. Applicants traverse on the grounds that the agent of claim 32 was already searched as shown in the office action dated December 20, 2005 in which several prior art rejections were made. The inventions of groups I and II share special technical features in that they are both agents for inhibiting the development or progress of proliferative diseases, cancer diseases or other diseases which are accompanied by elevated PLK1 expression levels, they both reduce or inhibit the activity of mammalian polo like kinase I in mammalian cells and they both include at least one phosphorothioate antisense oligonucleotide.

In the event this paper is not considered to be timely filed, the Applicant respectfully petitions for an appropriate extension of time. Any fee for such an extension together with any additional fees that may be due with respect to this paper, may be charged to Counsel's Deposit Account No. 02-2135.

Respectfully submitted,

By  #22980  
for

Monica Chin Kitts  
Attorney for Applicant  
Registration No. 36,105  
ROTHWELL, FIGG, ERNST & MANBECK  
1425 K. Street, Suite 800  
Washington, D.C. 20005  
Telephone: (202) 783-6040

MCK/cb